Breast cancer surgery - Historical evolution, current status and future perspectives

被引:27
作者
Sakorafas, GH [1 ]
机构
[1] 251 Hellen Air Force Gen Hosp, Dept Surg, Athens, Greece
关键词
D O I
10.1080/028418601750070984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The diagnosis and management of breast cancer have changed dramatically over the past two decades in response not only to new technologies but also to cultural and social aspects of the disease. Mastectomy (either radical or modified radical) was the historical mainstay of the treatment of breast cancer for decades. Although mastectomy continues to be appropriate for some patients, breast conservation has become the preferred method of treatment for many patients. Meeting the dual goal of optimum cosmesis and minimal rates of in-breast recurrences after breast-conservation therapy requires the selection and integration of appropriate diagnostic methods (including breast imaging techniques and breast biopsy techniques) as well as therapeutic methods (breast irradiation techniques, and systemic cytotoxic and hormonal therapy). To achieve optimal breast-conservation treatment, a multidisciplinary approach is necessary. Mastectomy followed by breast reconstruction is a valuable alternative for patients who require or choose mastectomy. After tumor downstaging with induction chemotherapy, a large percentage of patients with large or locally advanced tumors will be able to undergo breast-conservation therapy. Partial (levels I and II) axillary lymph node dissection remains the standard of care in the surgical management of patients with invasive breast cancer. Recently, there has been intense interest in selective axillary lymph node dissection, focused mainly on the identification of patients who are likely to benefit from axillary lymph node dissection, using sentinel lymph node biopsy.
引用
收藏
页码:5 / 18
页数:14
相关论文
共 240 条
[51]  
ESTABROOK A, 1997, MULTIDISCIPLINARY AT, P1
[52]  
EVANS GRD, 1995, PLAST RECONSTR SURG, V96, P1111, DOI 10.1097/00006534-199510000-00016
[53]  
Ferzli George S., 1999, Breast J, V5, P26, DOI 10.1046/j.1524-4741.1999.005001026.x
[54]  
Feyerabend T, 1996, ONCOLOGY, V53, P214
[55]  
FILBERTI A, 1990, EUR J PLAST SURG, V13, P55
[56]   SIGNIFICANCE OF IPSILATERAL BREAST-TUMOR RECURRENCE AFTER LUMPECTOMY [J].
FISHER, B ;
ANDERSON, S ;
FISHER, ER ;
REDMOND, C ;
WICKERHAM, DL ;
WOLMARK, N ;
MAMOUNAS, EP ;
DEUTSCH, M ;
MARGOLESE, R .
LANCET, 1991, 338 (8763) :327-331
[57]   Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].
Fisher, B ;
Brown, A ;
Mamounas, E ;
Wieand, S ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Fisher, ER ;
Wickerham, DL ;
Wolmark, N ;
DeCillis, A ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493
[58]  
FISHER B, 1992, SEMIN SURG ONCOL, V8, P153
[59]   REANALYSIS AND RESULTS AFTER 12 YEARS OF FOLLOW-UP IN A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY WITH LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
ANDERSON, S ;
REDMOND, CK ;
WOLMARK, N ;
WICKERHAM, DL ;
CRONIN, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22) :1456-1461
[60]   8-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY AND LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
REDMOND, C ;
POISSON, R ;
MARGOLESE, R ;
WOLMARK, N ;
WICKERHAM, L ;
FISHER, E ;
DEUTSCH, M ;
CAPLAN, R ;
PILCH, Y ;
GLASS, A ;
SHIBATA, H ;
LERNER, H ;
TERZ, J ;
SIDOROVICH, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (13) :822-828